FDA warned Brilliant Enterprises that its mushroom products are unapproved new drugs because website and social media claims say they treat diseases.
What happened
FDA reviewed the company's website in June and July 2021 and its Instagram and Twitter accounts. FDA found claims that Lion's Mane, BoomChaga, CordaCex, and LVL:MAX cure, mitigate, treat, or prevent diseases such as cancer, diabetes, depression, anxiety, ulcers, and irritable bowel syndrome. FDA says these claims make the products drugs, but they are not FDA-approved.
What FDA found
FDA says the products are unapproved new drugs because they are intended to treat disease but have no FDA approval.
Section 201(p), 301(d), and 505(a) of the Act [21 U.S.C. 321(p), 331(d), 355(a)]FDA says the website and social media claims show the products are intended to cure, mitigate, treat, or prevent disease.
Section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]FDA says the products are misbranded because they lack adequate directions for a layperson to use them safely for their intended disease uses.
Section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5FDA says selling these misbranded drugs in interstate commerce violates the Act.
Section 301(a) of the Act [21 U.S.C. 331(a)]
What FDA wants
FDA asks the company to notify it in writing within 15 working days of the specific steps taken to address the violations, including how it will prevent recurrence and related documentation. If correction cannot be completed in that time, the company must explain the delay and state when it will finish.
Who should pay attention
- dietary supplement and mushroom product sellers
- companies making disease claims on websites or social media
- brands using social media marketing for supplements
This is a summary. Read the original letter on fda.gov.